An Additional LDL-Lowering Effect of Amlodipine; Not Only an Antihypertensive?-Reference-Cited by-同舟云学术

An Additional LDL-Lowering Effect of Amlodipine; Not Only an Antihypertensive?

Published:2012-11-30 Issue:6 Volume:35 Page:449-453
ISSN:1064-1963
Container-title:Clinical and Experimental Hypertension
language:en
Short-container-title:Clinical and Experimental Hypertension

Author:

Arslan Zekeriya,Ay Seyit Ahmet,Karaman Murat,Cakar Mustafa,Celik Turgay,Balta Sevket,Akhan Muharrem,Sarlak Hakan,Arslan Erol,Demirbas Seref,Demirkol Sait,Bulucu Fatih,Saglam Kenan

Publisher

Informa UK Limited

Subject

General Medicine,Physiology,Internal Medicine

Link

http://www.tandfonline.com/doi/pdf/10.3109/10641963.2012.746355

Reference27 articles.

1. Hypertension and Associated Metabolic Abnormalities — The Role of Insulin Resistance and the Sympathoadrenal System

2. Dyslipidemia and the Risk of Incident Hypertension in Men

3. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies

4. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): A position paper of the National Kidney Foundation

5. Effects of β-blockers on the Concentration and Oxidizability of Plasma Lipids

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Randomized trial of an increased dose of calcium channel blocker or angiotensin II type 1 receptor blocker as an add-on intensive depressor therapy in type 2 diabetes mellitus patients with uncontrolled essential hypertension: the ACADEMIE Study;Heart and Vessels;2018-11-08

2. A Randomized, Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and the Tolerability of a Triple Combination of Amlodipine/Losartan/Rosuvastatin in Patients With Comorbid Essential Hypertension and Hyperlipidemia;Clinical Therapeutics;2017-12

3. The Effects of Valsartan and Amlodipine on the Levels of Irisin, Adropin, and Perilipin;Clinical Laboratory;2015